GGrantIndex
← Leaderboards

James M Cook

University Of Wisconsin Milwaukee

$10,479,163
Attributed
$12,013,069
Total exposure
7
Grants
5
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.6M · FY200517
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17

Funding mix

By agency

NIH$12,013,069 · 7

By mechanism

R01$10,933,873 · 5
P30$570,827 · 1
R43$508,369 · 1

Top collaborators

Others in their field

Top investigators on “Ligands

Research focus

LigandsLeadBasePharmaceutical PreparationsPropertyAdverse EffectsReceptorDesignStructureFunctional DisorderEvaluationBenzodiazepinesIn VivoRattusAgonistMediatingBrainMissionQuality Of LifeMuscle RelaxantsAffectBenzodiazepine ReceptorAnticonvulsantsExhibits

Grant awards (35)

Development of new drugs for asthma by targeting GABA(A) receptors in the lung$478,857
R01 · FY2017 · HL · contact PI
Design of New Therapeutic Agents to Treat Schizophrenia$371,529
R01 · FY2017 · MH · contact PI
Development of new drugs for asthma by targeting GABA(A) receptors in the lung$478,857
R01 · FY2016 · HL · contact PI
Design of New Therapeutic Agents to Treat Schizophrenia$371,529
R01 · FY2016 · MH · contact PI
Development of new drugs for asthma by targeting GABA(A) receptors in the lung$471,673
R01 · FY2015 · HL · contact PI
Design of New Therapeutic Agents to Treat Schizophrenia$371,529
R01 · FY2015 · MH · contact PI
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic Pain$318,422
R01 · FY2015 · NS · contact PI
Development of new drugs for asthma by targeting GABA(A) receptors in the lung$529,192
R01 · FY2014 · HL · contact PI
Design of New Therapeutic Agents to Treat Schizophrenia$371,529
R01 · FY2014 · MH · contact PI
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic Pain$317,717
R01 · FY2014 · NS · contact PI
Design of New Therapeutic Agents to Treat Schizophrenia$383,904
R01 · FY2013 · MH · contact PI
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic Pain$307,277
R01 · FY2013 · NS · contact PI
Synthesis of Alpha2/Alpha3 GABA Agonists to Treat Neuropathic Pain$318,422
R01 · FY2012 · NS · contact PI
Targeting System Xc- for the Treatment of Addiction$660,133
R01 · FY2010 · DA
Design and Synthesis of Anxioselective Anxiolytics$449,201
R01 · FY2010 · MH · contact PI
Targeting System Xc- for the Treatment of Addiction$773,859
R01 · FY2009 · DA
Design and Synthesis of Anxioselective Anxiolytics$442,211
R01 · FY2009 · MH · contact PI
Development of Compounds Targeting xc- for the Treatment of Schizophrenia$250,489
R43 · FY2009 · MH
FLOW CYTOMETRY FACILITY$158,434
P30 · FY2009 · CA · contact PI
Design and Synthesis of Anxioselective Anxiolytics$438,704
R01 · FY2008 · MH · contact PI
Development of Compounds Targeting xc- for the Treatment of Schizophrenia$257,880
R43 · FY2008 · MH
FLOW CYTOMETRY FACILITY$107,713
P30 · FY2008 · CA · contact PI
Design and Synthesis of Anxioselective Anxiolytics$438,422
R01 · FY2007 · MH · contact PI
FLOW CYTOMETRY FACILITY$104,576
P30 · FY2007 · CA · contact PI
Design and Synthesis of Anxioselective Anxiolytics$473,707
R01 · FY2006 · MH · contact PI
FLOW CYTOMETRY FACILITY$101,530
P30 · FY2006 · CA · contact PI
SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDS$475,029
R01 · FY2005 · MH
FLOW CYTOMETRY FACILITY$98,574
P30 · FY2005 · CA
SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDS$322,731
R01 · FY2004 · MH
Selective Anxiolytics via BzR Subtype Specific Ligands$101,500
R01 · FY2004 · MH
SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDS$56,264
R01 · FY2004 · MH
SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDS$322,952
R01 · FY2003 · MH
SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDS$359,666
R01 · FY2002 · MH
SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDS$359,871
R01 · FY2001 · MH
SELECTIVE ANXIOLYTICS VIA BZR SUBTYPE SPECIFIC LIGANDS$169,186
R01 · FY2000 · MH